Allovir Net Worth
Allovir Net Worth Breakdown | ALVR |
Allovir Net Worth Analysis
Allovir's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Allovir's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Allovir's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Allovir's net worth analysis. One common approach is to calculate Allovir's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Allovir's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Allovir's net worth. This approach calculates the present value of Allovir's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Allovir's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Allovir's net worth. This involves comparing Allovir's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Allovir's net worth relative to its peers.
Enterprise Value |
|
To determine if Allovir is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Allovir's net worth research are outlined below:
| Allovir generated a negative expected return over the last 90 days | |
| Allovir has high historical volatility and very poor performance | |
| Allovir has some characteristics of a very speculative penny stock | |
| Allovir has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (190.42 M) with profit before overhead, payroll, taxes, and interest of 165 K. | |
| Allovir currently holds about 172.67 M in cash with (124.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.91, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Allovir has a poor financial position based on the latest SEC disclosures | |
| Roughly 49.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Allovir stock touches 52-week low at 0.47 amid market challenges - Investing.com |
Allovir uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Allovir. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Allovir's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Allovir's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Allovir is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Allovir backward and forwards among themselves. Allovir's institutional investor refers to the entity that pools money to purchase Allovir's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Rbf Llc | 2024-09-30 | 449 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 324.7 K | Fmr Inc | 2024-09-30 | 310.6 K | D. E. Shaw & Co Lp | 2024-09-30 | 296.5 K | Two Sigma Investments Llc | 2024-09-30 | 295.2 K | State Street Corp | 2024-09-30 | 222.4 K | Commonwealth Equity Services Inc | 2024-09-30 | 201 K | Marquette Asset Management Inc. | 2024-09-30 | 178.9 K | Jane Street Group Llc | 2024-06-30 | 173 K | Ecor1 Capital, Llc | 2024-09-30 | 11.3 M | Octagon Capital Advisors Lp | 2024-09-30 | 11.2 M |
Follow Allovir's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 85.25 M.Market Cap |
|
Project Allovir's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.00) | (0.95) | |
| Return On Capital Employed | (1.12) | (1.17) | |
| Return On Assets | (1.00) | (0.95) | |
| Return On Equity | (1.31) | (1.24) |
When accessing Allovir's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Allovir's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Allovir's profitability and make more informed investment decisions.
Evaluate Allovir's management efficiency
Allovir has return on total asset (ROA) of (0.3653) % which means that it has lost $0.3653 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8033) %, meaning that it created substantial loss on money invested by shareholders. Allovir's management efficiency ratios could be used to measure how well Allovir manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/16/2024, Return On Tangible Assets is likely to grow to -0.95. In addition to that, Return On Capital Employed is likely to drop to -1.17. At this time, Allovir's Total Assets are relatively stable compared to the past year. As of 12/16/2024, Other Current Assets is likely to grow to about 5.1 M, while Non Current Assets Total are likely to drop slightly above 3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.40 | 2.59 | |
| Tangible Book Value Per Share | 1.40 | 2.59 | |
| Enterprise Value Over EBITDA | (0.04) | (0.04) | |
| Price Book Value Ratio | 0.49 | 0.51 | |
| Enterprise Value Multiple | (0.04) | (0.04) | |
| Price Fair Value | 0.49 | 0.51 | |
| Enterprise Value | 8 M | 7.6 M |
The leadership approach at Allovir's fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Return On Equity (0.80) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Allovir insiders, such as employees or executives, is commonly permitted as long as it does not rely on Allovir's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Allovir insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Allovir time-series forecasting models is one of many Allovir's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Allovir's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Allovir Earnings per Share Projection vs Actual
Allovir Corporate Management
| Sonia Choi | Senior Relations | Profile | |
| Agustin MD | Advisor | Profile | |
| Dana MBA | VP Operations | Profile | |
| Ann Leen | Chief Officer | Profile | |
| Cintia PharmD | Chief Officer | Profile | |
| David Hallal | Executive Board | Profile | |
| Jeroen Beek | Consultant | Profile |
Already Invested in Allovir?
The danger of trading Allovir is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Allovir is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Allovir. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Allovir is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Allovir Stock Analysis
When running Allovir's price analysis, check to measure Allovir's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allovir is operating at the current time. Most of Allovir's value examination focuses on studying past and present price action to predict the probability of Allovir's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allovir's price. Additionally, you may evaluate how the addition of Allovir to your portfolios can decrease your overall portfolio volatility.